Skip to main content
. Author manuscript; available in PMC: 2013 Oct 31.
Published in final edited form as: Curr Drug Targets. 2010 Nov;11(11):1423–1429. doi: 10.2174/1389450111009011423

Fig. 6.

Fig. 6

Actuarial patient survival of subjects who underwent TBI-based BMT at the Medical College of Wisconsin, as part of a randomized trial of captopril versus placebo. Those who were on captopril (gray line) had a significantly better long term survival, p=0.03, compared to those on either placebo or those who did not participate in the study (black line). This figure includes data from Cohen et al. [17].